# AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Source: https://onco.cc/trials/nct06137144/  
OnCo record `nct06137144` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD3470, Pembrolizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.

## Summary

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. is a phase 1/2 interventional study registered as NCT06137144 by AstraZeneca, with 161 participants planned, started 2024-01-23 and due to reach its primary completion in 2029-05-03. Interventions recorded: AZD3470, Pembrolizumab. Conditions listed: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06137144
- Phase: 1/2
- Setting: A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies
- Sponsor: AstraZeneca
- Enrolled: 161

## Sources

- ClinicalTrials.gov NCT06137144: https://clinicaltrials.gov/study/NCT06137144

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [AZD3470](https://onco.cc/drugs/azd3470/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06137144.json